PMID- 11394733
OWN - NLM
STAT- MEDLINE
DCOM- 20011011
LR  - 20190921
IS  - 0149-2918 (Print)
IS  - 0149-2918 (Linking)
VI  - 23
IP  - 5
DP  - 2001 May
TI  - A comparison of the effects on saliva output of oxybutynin chloride and 
      tolterodine tartrate.
PG  - 753-60
AB  - BACKGROUND: Oxybutynin chloride and tolterodine tartrate are anticholinergic 
      agents used to suppress involuntary bladder contractions in urinary incontinence. 
      They act by inhibiting binding of acetylcholine to the muscarinic receptors in 
      the detrusor muscle of the bladder. The same types of muscarinic receptors are 
      found in the salivary glands; thus anticholinergic agents may decrease saliva 
      production and cause dry mouth, a commonly cited reason for discontinuation of 
      therapy. OBJECTIVE: The primary objective of this study was to compare saliva 
      output, which is an objective measure of dry mouth, in subjects taking immediate- 
      or extended-release oxybutynin, tolterodine, or placebo. METHODS: This was a 
      single-site, single-dose, randomized, double-blind, 4-treatment, 4-period 
      crossover study. Subjects were randomly assigned to 1 of 4 treatment sequences 
      that included extended-release oxybutynin 10 mg, tolterodine 2 mg, 
      immediate-release oxybutynin 5 mg, and placebo. Saliva output was measured 
      objectively before dosing with each treatment and at 0.5, 1, 2, 3, 4, 6, 8, 10, 
      and 12 hours after dosing. RESULTS: Thirty-six healthy adult volunteers (22 women 
      and 14 men) participated in the study. They ranged in age from 19 to 42 years 
      (mean, 27 years). Thirty-one were white, 3 Asian, and 2 black. There were no 
      significant differences in predose saliva output between the 4 study groups. With 
      placebo, saliva output increased throughout the day. Saliva output was maintained 
      at predose levels throughout the day with extended-release oxybutynin. Two hours 
      after dosing with tolterodine and immediate-release oxybutynin, saliva output 
      decreased nearly 0.5 g in specimens collected over 2 minutes. All 3 active 
      treatments were associated with lower saliva output compared with placebo. 
      Extended-release oxybutynin and tolterodine were similar with respect to area 
      under the saliva concentration-time curve but were associated with significantly 
      greater saliva output than was immediate-release oxybutynin (P < 0.01). There 
      were no serious adverse events (AEs) in this study. AEs were similar between 
      treatments, although the incidence of headache was higher in the active-treatment 
      groups than with placebo. CONCLUSIONS: Objective assessment of saliva output in 
      healthy adult volunteers indicated that extended-release oxybutynin and 
      tolterodine had less impact on saliva output than did conventional 
      immediate-release oxybutynin, suggesting that they may yield lower levels of dry 
      mouth.
FAU - Chancellor, M B
AU  - Chancellor MB
AD  - Department of Urology, University of Pittsburgh School of Medicine, Pennsylvania 
      15213, USA. chancellormb@msx.upmc.edu
FAU - Appell, R A
AU  - Appell RA
FAU - Sathyan, G
AU  - Sathyan G
FAU - Gupta, S K
AU  - Gupta SK
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Cholinergic Antagonists)
RN  - 0 (Cresols)
RN  - 0 (Mandelic Acids)
RN  - 0 (Tartrates)
RN  - 33RU150WUN (Phenylpropanolamine)
RN  - 5T619TQR3R (Tolterodine Tartrate)
RN  - K9P6MC7092 (oxybutynin)
SB  - IM
CIN - J Urol. 2005 Aug;174(2):588-9. PMID: 16006904
MH  - Adult
MH  - Area Under Curve
MH  - Benzhydryl Compounds/adverse effects/*pharmacology
MH  - Cholinergic Antagonists/adverse effects/*pharmacology
MH  - Cresols/adverse effects/*pharmacology
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Female
MH  - Headache/chemically induced
MH  - Humans
MH  - Male
MH  - Mandelic Acids/adverse effects/*pharmacology
MH  - *Phenylpropanolamine
MH  - Saliva/metabolism
MH  - Salivation/*drug effects
MH  - Tartrates/adverse effects/*pharmacology
MH  - Tolterodine Tartrate
EDAT- 2001/06/08 10:00
MHDA- 2001/10/12 10:01
CRDT- 2001/06/08 10:00
PHST- 2001/06/08 10:00 [pubmed]
PHST- 2001/10/12 10:01 [medline]
PHST- 2001/06/08 10:00 [entrez]
AID - S0149291801800242 [pii]
AID - 10.1016/s0149-2918(01)80024-2 [doi]
PST - ppublish
SO  - Clin Ther. 2001 May;23(5):753-60. doi: 10.1016/s0149-2918(01)80024-2.